Myriad Genetics Q2 2024 Adj. EPS $0.05 Beats $(0.01) Estimate, Sales $211.500M Beat $204.954M Estimate
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics (NASDAQ:MYGN) reported Q2 2024 adjusted EPS of $0.05, significantly beating the analyst estimate of $(0.01). The company also reported sales of $211.5 million, surpassing the $204.954 million estimate and marking a 15.26% increase from the same period last year.
August 06, 2024 | 8:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics reported Q2 2024 adjusted EPS of $0.05, beating the $(0.01) estimate by 600%. Sales of $211.5M also surpassed the $204.954M estimate, showing a 15.26% YoY increase.
The significant beat on both EPS and sales estimates, along with a notable year-over-year sales increase, is likely to positively impact MYGN's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100